- Molecular NameRifapentine
- SynonymCyclopentyl rifampin
- Weight877.045
- Drugbank_IDDB01201
- ACS_NO61379-65-5
- Show 2D model
- LogP (experiment)5.29
- LogP (predicted, AB/LogP v2.0)5.87
- pkaN/A
- LogD (pH=7, predicted)2.87
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.77
- LogSw (predicted, AB/LogsW2.0)0.1
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors6
- No.of HBond Acceptors16
- No.of Rotatable Bonds6
- TPSA220.15
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antibiotic drug used in the treatment of tuberculosis.
- Absorption_valueN/A
- Absorption (description)Rapidly and well absorbed from the gastrointestinal tract.
- Caco_2N/A
- Bioavailability70.0
- Protein binding97.7
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic
- Half lifeN/A
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityHyperuricemia is the most common adverse event in patients received Rifapentine (21.3%). Other side effects reported with frequency more than 5% are increased levels of ALT and AST, Neutropenia, Pyuria, Proteinuria, Lymphopenia.
- LD50 (rat)N/A
- LD50 (mouse)N/A